About this episode

This episode discusses Survodutide, an experimental weight-loss medication that targets dual receptors to improve metabolic health.

The provided text introduces Survodutide , an experimental weight-loss medication being developed by Boehringer Ingelheim and Zealand Pharma . Unlike traditional treatments that only target the GLP-1 receptor , this "twincretin" also activates the glucagon receptor to increase energy expenditure and aggressively target liver fat . Clinical trial data highlights significant weight reduction and dramatic improvements in metabolic health , specifically regarding MASLD and visceral fat loss . While the medication shares common gastrointestinal side effects with existing drugs, the biohacking community is particularly interested in its potential to preserve lean mass and enhance fat burning. This information is intended for use in a podcast format , which is noted as being sponsored by InfinityPeptide.com .

Topics covered

• weight loss
• metabolic health
• dual receptor agonism
• clinical trials
• biohacking

Keywords

• Survodutide
• weight loss
• metabolic health
• GLP-1 receptor
• glucagon receptor
• clinical trials
• biohacking

Sponsors

Infinity Peptides

Mentioned in this episode

Organizations: Boehringer Ingelheim, Zealand Pharma

Products: Survodutide

More episodes of Today's discussion

• Pinealon: The Science and Hype of Brain Bioregulators · September 7, 2026 · 21 min
• Dulaglutide: The Foundation of Modern Metabolic Medicine · August 31, 2026 · 21 min
• FOXO4-DRI: The Science and Hype of Senolytic Peptides · August 24, 2026 · 26 min
• Cerebrolysin: Clinical Science and Biohacking Analysis · August 17, 2026 · 23 min
• ADAMAX Peptide: Science, Hype, and Cognitive Potential · August 10, 2026 · 19 min
• DT-109: The Tripeptide Frontier of Metabolic Health · July 27, 2026 · 23 min

Explore listener stats, chart rankings, contacts and more on the Today's discussion podcast page.